19 November 2015 – Congratulations to Adapt Pharma for their recent NDA approval of NARCAN® (naloxone hydrochloride) nasal spray. PLC guided development of NARCAN, a needle-free nasal spray for the treatment of opioid drug overdose, and filed both the successful Fast Track Designation application and the NDA on behalf of Adapt. PLC looks forward to supporting Adapt with the NARCAN post approval filings.
NARCAN® (naloxone hydrochloride) Nasal Spray approved by U.S. food and drug administration
- First Ready-To-Use Needle-free Nasal Spray Treats Opioid Overdose Emergency